| Placebo | Zonisamide | CPAP | |
| Subjects | 15 | 13 | 13 |
| Males/females | 13/2 | 13/0 | 12/1 |
| Age years | 53±14 | 55±10 | 44±10# |
| Treated hypertension % | 50 | 46 | 15 |
| BMI kg·m−2 | 31±2 | 31±3 | 31±2 |
| Waist/hip ratio | 0.99±0.06 | 1.03±0.10* | 1.01±0.07 |
| Neck circumference cm | 43±2 | 44±2 | 44±3 |
| Systolic BP mmHg | 137±19 | 141±16 | 132±20 |
| Diastolic BP mmHg | 84±8 | 84±10 | 83±7 |
| Heart rate beats·min−1 | 59±10 | 59±7 | 66±6#,¶ |
| AHI events·h−1 | 50±23 | 42±24 | 48±26 |
| ODI events·h−1 | 43±21 | 35±21 | 44±25 |
| ESS score | 12±4 | 13±6 | 14±4 |
Data are presented as n or mean±sd, unless otherwise stated. CPAP: continuous positive airway pressure; BMI: body mass index; BP: blood pressure; AHI: apnoea/hypopnoea index; ODI: oxygen desaturation index; ESS: Epworth Sleepiness Scale. *: p<0.05 for zonisamide versus placebo; #: p<0.05 for CPAP versus zonisamide; ¶: p<0.05 for CPAP versus placebo.